Cargando…

Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease

We conducted a phase 2 study in which patients undergoing allogeneic hematopoietic stem cell transplantation received tocilizumab in addition to standard immune suppression with tacrolimus and methotrexate for graft-versus-host disease prophylaxis. Thirty-five patients were enrolled between January...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drobyski, William R., Szabo, Aniko, Zhu, Fenlu, Keever-Taylor, Carolyn, Hebert, Kyle M., Dunn, Renee, Yim, Sharon, Johnson, Bryon, D’Souza, Anita, Eapen, Mary, Fenske, Timothy S., Hari, Parameswaran, Hamadani, Mehdi, Horowitz, Mary M., Rizzo, J. Douglas, Saber, Wael, Shah, Nirav, Shaw, Bronwen, Pasquini, Marcelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865423/ https://www.ncbi.nlm.nih.gov/pubmed/29351985 http://dx.doi.org/10.3324/haematol.2017.183434

Ejemplares similares

The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation
por: Taylor, Mallory R., et al.
Publicado: (2022)

P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA
por: Shah, Nirav N, et al.
Publicado: (2023)

DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation
por: Dhakal, B., et al.
Publicado: (2016)

Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination
por: Chhabra, Saurabh, et al.
Publicado: (2022)

The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill
por: Knight, Jennifer M., et al.
Publicado: (2021)

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy
por: Furqan, Fateeha, et al.
Publicado: (2022)

Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia
por: Eapen, Mary, et al.
Publicado: (2020)

Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014
por: D’Souza, Anita, et al.
Publicado: (2017)

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2019)

Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
por: Hamilton, Betty K., et al.
Publicado: (2023)

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
por: Shah, Nirav N., et al.
Publicado: (2019)

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis
por: D'Souza, Anita, et al.
Publicado: (2017)

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
por: Dhakal, Binod, et al.
Publicado: (2021)

Methotrexate/tacrolimus/vorinostat: Lack of efficacy: case report
Publicado: (2022)

Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis
por: Isozaki, Takeo, et al.
Publicado: (2010)

Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial
por: D'Souza, Anita, et al.
Publicado: (2020)

Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol
por: Johnson, Alexander K., et al.
Publicado: (2022)

PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response
por: Zurko, Joanna, et al.
Publicado: (2021)

Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis
por: Narváez, Javier, et al.
Publicado: (2015)

Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation
por: Knight, Jennifer M., et al.
Publicado: (2018)

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients
por: Abid, Muhammad Bilal, et al.
Publicado: (2022)

Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis
por: Hamadani, Mehdi, et al.
Publicado: (2020)

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)
por: Kaneko, Yuko, et al.
Publicado: (2016)

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
por: Frigault, Matthew J., et al.
Publicado: (2020)

Summer‐type hypersensitivity pneumonitis in a patient with rheumatoid arthritis on methotrexate and tacrolimus
por: Ohkubo, Hirotsugu, et al.
Publicado: (2016)

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
por: O’Mahony, Alison, et al.
Publicado: (2018)

Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies
por: Mohan, Meera, et al.
Publicado: (2022)

Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate
por: Benucci, Maurizio, et al.
Publicado: (2017)

Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy
por: Knight, Jennifer M., et al.
Publicado: (2022)

Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate
por: Lee, Won-Seok, et al.
Publicado: (2016)

Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?
por: Witte, Torsten
Publicado: (2015)

Assessment and Comparison of the Efficacy of Methotrexate, Prednisolone, Adalimumab, and Tocilizumab on Multipotency of Mesenchymal Stem Cells
por: Liu, Shuang, et al.
Publicado: (2020)

Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab
por: Teitsma, Xavier M., et al.
Publicado: (2020)

Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft‐versus‐host disease prophylaxis
por: Garming Legert, Karin, et al.
Publicado: (2020)

Steroid-Sparing Effect of Tocilizumab and Methotrexate in Patients with Polymyalgia Rheumatica: A Retrospective Cohort Study
por: Izumi, Keisuke, et al.
Publicado: (2021)

Letter to the Editor Regarding “Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation”
por: Chhabra, Saurabh, et al.
Publicado: (2020)

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
por: Jones, G, et al.
Publicado: (2010)

Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: A STROBE-compliant article
por: Wang, Chun-yan, et al.
Publicado: (2019)

Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study
por: Mori, Shunsuke, et al.
Publicado: (2019)

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fajpq9cmg8qae0p5505a7ibn24